Ramosetron | CAS# 132036-88-5 | Biochemical

MedKoo Cat#: 577967 | Name: Ramosetron

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ramosetron is a serotonin 5-HT3 receptor antagonist used to treat diarrhea-predominant irritable bowel syndrome and nausea.

Chemical Structure

Ramosetron

CAS#132036-88-5

Theoretical Analysis

MedKoo Cat#: 577967

Name: Ramosetron

CAS#: 132036-88-5

Chemical Formula: C17H17N3O

Exact Mass: 279.1372

Molecular Weight: 279.34

Elemental Analysis: C, 73.10; H, 6.13; N, 15.04; O, 5.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ramosetron; YM-060; YM 060; YM060; Nor-YM 060; Nasea

IUPAC/Chemical Name

(R)-(1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzo[d]imidazol-5-yl)methanone

InChi Key

NTHPAPBPFQJABD-LLVKDONJSA-N

InChi Code

InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1

SMILES Code

Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c4ccccc14

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 279.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kim TK, Cho YJ, Lim CW, Min JJ, Choi EK, Hong DM, Jeon Y. Effect of ramosetron on QTc interval: a randomised controlled trial in patients undergoing off-pump coronary artery bypass surgery. BMC Anesthesiol. 2016 Aug 3;16(1):56. doi: 10.1186/s12871-016-0222-1. PubMed PMID: 27488394; PubMed Central PMCID: PMC4972982. 2: Joo J, Park S, Park HJ, Shin SY. Ramosetron versus ondansetron for postoperative nausea and vomiting in strabismus surgery patients. BMC Anesthesiol. 2016 Jul 22;16(1):41. doi: 10.1186/s12871-016-0210-5. PubMed PMID: 27449404; PubMed Central PMCID: PMC4957928. 3: Lee YH, Seo JH, Min KT, Lim YJ, Jeong SW, Lee EK, Choi BM, Noh GJ. Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. Br J Clin Pharmacol. 2016 Sep;82(3):762-72. doi: 10.1111/bcp.13010. Epub 2016 Jun 8. PubMed PMID: 27195435. 4: Song HJ, Seo HJ, Son H. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016 Aug 15. [Epub ahead of print] Review. PubMed PMID: 27526189. 5: Wangnamthip S, Chinachoti T, Amornyotin S, Wongtangman K, Sukantarat N, Noitasaeng P. A Randomized Placebo-Controlled Trial of Oral Ramosetron for Prevention of Post Operative Nausea and Vomiting after Intrathecal Morphine in Patients Undergoing Gynecological Surgery. J Med Assoc Thai. 2016 May;99(5):455-61. PubMed PMID: 27501597. 6: Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol. 2016 Sep;51(9):874-82. doi: 10.1007/s00535-016-1165-5. Epub 2016 Jan 22. PubMed PMID: 26800997. 7: Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. Gastroenterology. 2016 Feb;150(2):358-66.e8. doi: 10.1053/j.gastro.2015.10.047. Epub 2015 Nov 6. PubMed PMID: 26551550. 8: Song JW, Shim JK, Choi SH, Soh S, Jang J, Kwak YL. Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms. J Neurosurg Anesthesiol. 2016 Aug 25. [Epub ahead of print] PubMed PMID: 27564555. 9: Lee SH, Cho SY, Yoo KY, Jeong S. Population pharmacokinetics of ramosetron. J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):73-83. doi: 10.1007/s10928-015-9455-8. Epub 2015 Nov 11. PubMed PMID: 26558626. 10: Kim SH, Oh CS, Lee SJ. Efficacy of palonosetron and ramosetron on postoperative nausea and vomiting related to intravenous patient-controlled analgesia with opioids after gynecological laparoscopic surgery (double-blinded prospective randomized controlled trial). J Anesth. 2015 Aug;29(4):585-92. doi: 10.1007/s00540-015-1981-4. Epub 2015 Mar 4. PubMed PMID: 25735497.